1. Market Research
  2. > Healthcare
  3. > General Medicine and Specialty Medicine Market Trends
  4. > 2011 Radiotherapy Today and Tomorrow

2011 Radiotherapy Today and Tomorrow

  • December 2011
  • -
  • Frost & Sullivan

This study looks at emerging trends in the radiosurgery market and the residual impact of the financial crisis from both a market and an end-user hospital perspective. Stereotactic Radiosurgery (SRS) is an advanced form of radiotherapy capable of synchronizing tumor detection, surgical guidance, and radiation delivery components in a manner that can treat localized tumors. SRS systems, due to their accuracy and precision, minimize damage to healthy tissue, making them ideal for treatment of complicated tumors located near the brain or spine. This survey is intended to gather qualitative feedback on how radiosurgery centers plan to work around external challenges.

Table Of Contents

2011 Radiotherapy Today and Tomorrow
Table of Contents

Market Overview and Metrics 4
Case Study: Gamma Knife Surgery Program Perceptions 24
About Frost and Sullivan 45


View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

Non-Small Cell Lung Cancer: KOL Insight

Non-Small Cell Lung Cancer: KOL Insight

  • $ 7 495
  • Industry report
  • July 2015
  • by Firstword Pharma

Non-Small Cell Lung Cancer: KOL Insight offers detailed expert opinion on the continuing evolution of the treatment paradigm for EGFR/ALK positive and negative NSCLC, and the potential for targeting ...

Frontier Pharma: Versatile Innovation in Oncology - Identifying and Commercializing Versatile First-in-Class Innovation

Frontier Pharma: Versatile Innovation in Oncology - Identifying and Commercializing Versatile First-in-Class Innovation

  • $ 6 995
  • Industry report
  • July 2015
  • by GBI Research

Frontier Pharma: Versatile Innovation in Oncology - Identifying and Commercializing Versatile First-in-Class Innovation Summary The oncology therapy area comprises a large and diverse range of indications, ...

Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation

Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation

  • $ 6 995
  • Industry report
  • June 2015
  • by GBI Research

Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation Summary Pancreatic cancer is the 12th most common cancer globally, and the fourth most fatal, with a mortality ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.